Skip to main content
. Author manuscript; available in PMC: 2023 May 30.
Published in final edited form as: Crit Rev Oncog. 2022;27(2):73–84. doi: 10.1615/CritRevOncog.2022044635

TABLE 2:

Current and completed clinical trials examining radiosensitizers in HNC

NCT no. Phase Intervention Disease Study status
NCT00001442 31 I Paclitaxel, radiotherapy Head and neck squamous cell carcinoma Completed
NCT00410826 41 III Erlotinib hydrochloride, cisplatin, 3-dimensional conformal radiotherapy and intensity-modulated radiotherapy Stage III and IV squamous cell carcinoma of hypopharynx, larynx, lip and oral cavity, nasopharynx and oropharynx Completed
NCT04722523 49 I Cisplatin, carboplatin, docetaxel, cetuximab, cemiplimab, surgical resection, radiotherapy Head and neck squamous cell carcinoma Recruiting
NCT01384799 68 I Cisplatin, CUDC-101, radiotherapy Locally advanced head and neck squamous cell carcinoma Completed
NCT01880359 72 III Placebo, cisplatin, nimorazole Locally advanced, HPV negative head and neck squamous cell carcinoma Active, not recruiting
NCT02229656 66 I Olaparib, radiotherapy Stage II and III laryngeal cancer, head and neck squamous cell carcinoma Active, not recruiting
NCT01507467 74 III Nimorazole, accelerated fractionated radiotherapy Head and neck squamous cell carcinoma Terminated